Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 246

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 246
---
 business combinations
with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our Charter
or Bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate
actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer, or proxy contest.
These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of
your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes
in our board of directors could cause the market price of our Common Stock to decline.

If we engage in future acquisitions or strategic
partnerships, this may increase capital requirements, dilute stockholders, cause us to incur debt or assume contingent liabilities, and
subject us to other risks.

We intend to evaluate various
acquisition opportunities and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property rights,
technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:

●increased
                                            operating expenses and cash requirements;

●the
                                            assumption of additional indebtedness or contingent liabilities;

●the
                                            issuance of our equity securities;

●assimilation
                                            of operations, intellectual property and drugs of an acquired company, including difficulties
                                            associated with integrating new personnel;

●the
                                            diversion of our management’s attention from our existing drug programs and initiatives
                                            in pursuing such a strategic partnership, merger or acquisition;

●retention
                                            of key employees, the loss of key personnel and uncertainties in our ability to maintain
                                            key business relationships;

●risks
                                            and uncertainties associated with the other party to such a transaction, including the prospects
                                            of that party and their existing products or product candidates and marketing approvals;
                                            and

●our
                                            inability to generate revenue from acquired technology and/or products sufficient to meet
                                            our objectives in undertaking the acquisition or even to offset the associated acquisition
                                            and maintenance costs.

In addition, if we undertake
acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible
assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities,
and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development